---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Definition and etiology"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Definition and etiology. Topics: Definition: progressive motor, cognitive, and psychiatric disorder; Etiology: expanded CAG repeat in HTT encoding a polyglutamine tract; CAG repeat length thresholds; Reduced penetrance of 36 to 39 CAG repeat alleles; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Definition: progressive motor, cognitive, and psychiatric disorder

> “Huntington disease (HD) is a progressive disorder of motor, cognitive, and psychiatric manifestations.”
> “HD is inherited in an autosomal dominant manner. Offspring of an individual with a heterozygous CAG repeat expansion in HTT have a 50% chance of inheriting a CAG repeat expansion.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.1-2"></a>

### Etiology: expanded CAG repeat in HTT encoding a polyglutamine tract

> “The disease is caused by an expanded CAG trinucleotide repeat (of variable length) in HTT, the gene that encodes the protein huntingtin.”

Source: [Bates et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/27188817/)

> “Huntington's disease is an autosomal-dominant, progressive neurodegenerative disorder with a distinct phenotype, including chorea and dystonia, incoordination, cognitive decline, and behavioural difficulties.”

Source: [Walker (2007)](https://pubmed.ncbi.nlm.nih.gov/17240289/)

<a id="topic-2.2.1.1-3"></a>

### CAG repeat length thresholds

| Allele category | CAG repeat length |
| --- | --- |
| Normal alleles | “26 or fewer CAG repeats” |
| Intermediate alleles | “27 to 35 CAG repeats” |
| Reduced-penetrance HD-causing alleles | “36 to 39 CAG repeats” |
| Full-penetrance HD-causing alleles | “40 or more CAG repeats” |

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.1-4"></a>

### Reduced penetrance of 36 to 39 CAG repeat alleles

> “Variable penetrance for alleles carrying 36-39 repeats has been noted, but the disease appears fully penetrant when the repeat numbers are >40.”

Source: [Bean et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25356969/)

> “A total of 18 of 7,315 individuals had ≥36 CAG, revealing that approximately 1 in 400 individuals from the general population have an expanded CAG repeat associated with HD (0.246%).”
> “The infrequent diagnosis of HD at this CAG length is likely due to low penetrance.”

Source: [Kay et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4955276/)

<a id="topic-2.2.1.1-5"></a>

### CAG repeat length and age of onset

> “A significant inverse correlation exists between the number of HTT CAG repeats and the age of onset of HD”
> “On average, CAG repeat length accounts for up to 70% of the variability in age of onset, with an estimated 10%-20% of the residual variability being accounted for by heritable factors”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “For example, our model predicts a 91% chance that a 40-year-old individual with 42 repeats will have onset by the age of 65, with a 95% confidence interval from 90 to 93%.”

Source: [Langbehn et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15025718/)

<a id="topic-2.2.1.1-6"></a>

### Juvenile Huntington's disease and anticipation

> “Juvenile HD is rare and historically defined as HD with an onset of symptoms before age 20 years”
> “The proportion of individuals with juvenile HD varies from 1% to 15% of individuals diagnosed with HD”
> “Large expansions (i.e., an increase in allele size of >7 CAG repeats) occur almost exclusively through paternal transmission.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “HTT CAG repeat length in individuals with juvenile HD is usually >55 CAG repeats and is often caused by anticipation, usually via paternal transmission”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
